Clinical Trial Update: Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating a tailored-dose docetaxel regimen in metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED